Clover touts positive preclinical results for COVID-19 vaccine

By The Science Advisory Board staff writers

September 25, 2020 -- Clover Biopharmaceuticals has announced positive preclinical data regarding its protein-based COVID-19 S-Trimer vaccine candidate in combination with adjuvants from either GlaxoSmithKline (GSK) or Dynavax.

The pairing induces a strong immune response and protection against SARS-CoV-2 in animal models, according to the firm. Rhesus macaques that received the vaccine were protected against SARS-CoV-2 infection, as demonstrated by clinical observations (protection from weight loss and increases in body temperature) and significant reduction in viral loads in lung tissues and swabs, with no signs of disease enhancement, the firm said. Also, the vaccine produced a Th1-polarized T-cell response in mice, rats, and monkeys.

The positive preclinical data supports Clover's decision to progress adjuvanted vaccine candidates using both adjuvants into the firm's ongoing phase I clinical study of S-Trimer, which started in June. The study has completed its enrollment of 150 adult and elderly participants. Based on preliminary results, Clover is enrolling an additional 200 participants in a phase I dose-expansion study. The firm also intends to initiate a global phase II/III vaccine efficacy study before the end of the year.

Clover's clinical trials are supported by funding and collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI).


Copyright © 2020 scienceboard.net
 


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.